circulating tumor DNA
Foresight Diagnostics, Stanford, Others File Motions to Dismiss Roche Suit
Foresight said Roche failed to bring its trade-secret causes of action within the three-year statute of limitations.
AstraZeneca to Use Tracer Biotechnologies Cancer Monitoring Tech for Clinical Trials
Tracer has developed a proprietary platform for tumor-informed circulating-tumor DNA detection using digital PCR.
Natera Enrolls First Patients in Phase III SAGITTARIUS Colon Cancer Trial
Investigators are using the Signatera ctDNA test to guide treatment decisions for high-risk colon cancer patients based on their tumor genetics.
Foresight Diagnostics Launches Lymphoma Personalized Treatment Clinical Trial
The trial will study the use of Foresight's Clarity MRD assay in identifying early treatment responders for therapy de-escalation.
Final FDA Guidance Lays Path for Drugmakers to Establish Circulating Tumor DNA as Trial Endpoint
The guidance provides the agency's thoughts on the emerging use of ctDNA residual disease testing to select patients for treatment in trials of new adjuvant therapies.